Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Policy & Regulation
Trends & Finance
Stock
Trinity Bioscience returns to Nasdaq compliance
By
LabPulse.com staff writers
Trinity Bioscience has announced that the it has received notice from Nasdaq that it has now regained listing compliance for the market value of its shares.
November 8, 2024
BioAffinity secures $2.7M to advance novel lung cancer diagnostic test
By
LabPulse.com staff writers
Texas-based bioAffinity Technologies has secured nearly $2.7 million at the close of a registered direct stock offering that it will use for general corporate purposes, including working capital, to advance its novel CyPath Lung test.
October 24, 2024
T2 Biosystems to sell $8M in stock in private placement
By
LabPulse.com staff writers
T2 Biosystems has announced that it has signed a definitive agreement to sell approximately $8 million in shares and warrants to a group of investors.
May 16, 2024
T2 Biosystems granted Nasdaq listing extension
By
LabPulse.com staff writers
Nasdaq's Hearings Panel has granted T2 Biosystems' request for an extension for continued listing on the stock market subject to T2 complying with Nasdaq's rule for market value of listed securities.
March 12, 2024
Nasdaq issues delisting notice to T2 Biosystems
By
LabPulse.com staff writers
T2 Biosystems has received a delisting notice from Nasdaq after failing to satisfy the minimum $35 million market value of listed securities threshold required to remain listed.
November 27, 2023
Invitae receives noncompliance notice from NYSE
By
LabPulse.com staff writers
San Francisco-based medical genetics company Invitae received a notice of noncompliance from the New York Stock Exchange (NYSE) on September 20 for its stock price closing under $1.00 per share for 30 consecutive days.
September 25, 2023
Report: Lack of standardization a ‘huge’ issue during pandemic, problems persist
By
Nick Paul Taylor
A lack of standardization of infectious disease consumables was “a huge, unanticipated issue during the pandemic” that still needs to be resolved, according to a report in GenomeWeb.
September 15, 2023
Precipio prices $2M stock offering and concurrent private placement
By
LabPulse.com staff writers
The specialty cancer diagnostics company intends to use the net proceeds for working capital and general corporate purposes.
June 8, 2023
Trinity Biotech receives minimum-bid notice from Nasdaq
By
LabPulse.com staff writers
In accordance with the Nasdaq listing rule in question, Trinity has 180 calendar days, or until October 16, to regain compliance with the minimum bid price requirement.
April 25, 2023
Lucira Health files for bankruptcy despite receiving FDA green light
By
Leo O'Connor
The firm is seeking a strategic or financial partner for the resumption of manufacturing and development of additional home diagnostic testing products.
February 27, 2023
OpGen closes $7.5 million public offering
By
LabPulse.com staff writers
OpGen closed a public offering of an aggregate of 2.6 million shares of its common stock, Series A-1 warrants, to purchase the same amount of common stock and Series A-2 warrants at a combined public offering price of $2.90 per share.
January 17, 2023
OpGen announces one-for-20 reverse stock split
By
LabPulse.com staff writers
The reverse stock split, approved by its stockholders at a special meeting on November 30, has been implemented to increase the firm's share price so that it could regain compliance with Nasdaq’s minimum bid price listing requirement.
January 5, 2023
Page 1 of 4
Next Page